Nov 30, 2017

Febuxostat (Uloric) May Increase Risk of Heart-Related Death

Febuxostat was associated with an increased risk of cardiovascular and all-cause mortality, according to preliminary results from a safety clinical trial. In the safety trial, over 6,000 patients over the age of 50 with gout and a history of either cardiovascular or cerebrovascular disease were randomized to feboxustat or allopurinol once daily.... Read More